Herantis Pharma
Finland - EspooPharmaceutical
Focus: Herantis Pharma is a Finnish public biotech company focused on gene therapy and biologic treatments for neurological disorders, particularly Parkinson's disease. The company operates as a specialized neurology-focused biotech with a global development footprint but limited commercial scale.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Herantis Pharma
AI assessmentNot HiringNo open roles listed right now. Follow Herantis Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
8 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Lymfactin® [1 x 10E10 vp]
Secondary LymphedemaClinical Trials (1)
NCT02994771A Phase I Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema
Phase 1Help build intelligence for Herantis Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.